Home / Resource Library / A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell LymphomaA Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma